Regeneron reaches 52-week high amid market strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 07 Jan 26
Source: Coinmarketcap
Regeneron Pharmaceuticals Inc's stock rose by 3.02%, reaching a 52-week high, as the broader market showed positive momentum with the Nasdaq-100 up 0.14% and the S&P 500 up 0.11%.
This increase is attributed to the company's scheduled release of its Q4 and full year 2025 financial results on January 30, 2026, which demonstrates its commitment to transparency and investor communication. The upcoming earnings report is expected to provide insights into the company's performance and future growth potential, contributing to positive investor sentiment.
The strong performance of Regeneron reflects not only its operational strategies but also the overall market conditions that favor biotech stocks, enhancing investor confidence in the sector.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 771.250
Low
637.00
Averages
808.50
High
1057
Current: 771.250
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
